Shares of Oculis Holding AG (NASDAQ:OCS – Get Free Report) saw strong trading volume on Friday . 1,115,990 shares traded hands during mid-day trading, an increase of 212% from the previous session’s volume of 357,595 shares.The stock last traded at $23.4510 and had previously closed at $29.65.
Analyst Ratings Changes
Several research analysts have recently issued reports on the stock. Wall Street Zen downgraded shares of Oculis from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a research note on Tuesday, April 21st. JPMorgan Chase & Co. upped their target price on shares of Oculis from $38.00 to $42.00 and gave the stock an “overweight” rating in a research note on Monday, May 18th. Stifel Nicolaus upped their target price on shares of Oculis from $40.00 to $50.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Finally, Needham & Company LLC upped their target price on shares of Oculis from $40.00 to $46.00 and gave the stock a “buy” rating in a research note on Tuesday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $49.38.
Get Our Latest Research Report on Oculis
Oculis Trading Down 23.4%
Oculis (NASDAQ:OCS – Get Free Report) last issued its quarterly earnings data on Friday, May 8th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.14). The company had revenue of $0.26 million for the quarter, compared to the consensus estimate of $0.25 million. Oculis had a negative net margin of 8,460.67% and a negative return on equity of 56.78%. As a group, equities research analysts predict that Oculis Holding AG will post -2.21 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in OCS. China Universal Asset Management Co. Ltd. lifted its position in Oculis by 100.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock valued at $40,000 after purchasing an additional 1,000 shares during the period. Aventura Private Wealth LLC bought a new position in Oculis during the fourth quarter valued at approximately $80,000. Koshinski Asset Management Inc. bought a new position in Oculis during the first quarter valued at approximately $238,000. Millennium Management LLC purchased a new stake in Oculis during the fourth quarter valued at approximately $312,000. Finally, Marshall Wace LLP purchased a new stake in Oculis during the second quarter valued at approximately $393,000. Institutional investors own 22.30% of the company’s stock.
Oculis Company Profile
Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.
Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.
Featured Stories
- Five stocks we like better than Oculis
- Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys
- Salesforce Stock Finds Support as AI Momentum Builds
- Dollar Tree Keeps Winning After Family Dollar Divorce
- Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.
